N-Aminoazacyclooctan | 37546-30-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Aminoazacyclooctan
• 英文别名: azonan-1-ylamine；diazacyclononane；Azonan-1-amine；azonan-1-amine
• CAS: 37546-30-8
• 化学式: C₈H₁₈N₂
• 分子量: 142.244
• InChiKey: HGMVYKUPKTXUTH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Organometallic complex, light-emitting element, light-emitting device, electronic device, and lighting device
  申请人：Semiconductor Energy Laboratory Co., Ltd.

  公开号：US10170710B2

  公开（公告）日：2019-01-01

  Provided is an organometallic complex which emits light with a short wavelength and has high emission efficiency and high heat resistance. The organometallic complex includes a central metal; and a first ligand, a second ligand, a third ligand, and a fourth ligand which are coordinated to the central metal. The first ligand includes a triazole skeleton including nitrogen bonded to the central metal. The second ligand includes an indolo[3,2-b]carbazole skeleton whose 6-position is bonded to the central metal or a pyrido[2,3-b:6,5-b′]diindole skeleton whose 6-position is bonded to the central metal. The third ligand includes a benzene skeleton whose carbon is bonded to the central metal. The fourth ligand includes a pyridine skeleton whose nitrogen is bonded to the central metal or a benzene skeleton whose carbon is bonded to the central metal.

  本发明提供了一种有机金属配合物，它能发出短波长的光，并具有高发射效率和高耐热性。该有机金属配合物包括中心金属；以及与中心金属配位的第一配体、第二配体、第三配体和第四配体。第一配体包括与中心金属键合的含氮三唑骨架。第二配体包括 6 位与中心金属键合的吲哚并[3,2-b]咔唑骨架或 6 位与中心金属键合的吡啶并[2,3-b:6,5-b′]二吲哚骨架。第三个配体包括一个苯骨架，其碳与中心金属键合。第四配体包括一个吡啶骨架，其氮键与中心金属相连，或包括一个苯骨架，其碳键与中心金属相连。
• [EN] 1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF<br/>[FR] DÉRIVÉS D'INDAZOLE 5 -, 6-DISUBSTITUÉS, 1-PYRAZOLYLE, EN TANT QU'INHIBITEURS DE LRRK2, COMPOSITIONS PHARMACEUTIQUES ET UTILISATIONS CORRESPONDANTES
  申请人：MERCK SHARP & DOHME

  公开号：WO2020247298A2

  公开（公告）日：2020-12-10

  The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.